How Does the CAR-T Cell Therapy Process Work Step by Step?

Step 1 – Medical evaluation and eligibility review

Before anything begins, a specialized team reviews the patient’s diagnosis, previous treatments, current disease status, organ function, performance status and infection history. The goal is to determine whether CAR-T is medically appropriate and whether the patient is fit enough for the process. Not every patient with the same diagnosis will be a candidate. Imaging, blood tests, heart and lung assessment, and sometimes a bone marrow or biopsy review are part of this stage.

Step 2 – Leukapheresis (cell collection)

If the patient is accepted, the next step is to collect T cells from the blood. This procedure is called leukapheresis.

• Blood is drawn from a vein (or sometimes a central line), circulated through a machine that separates white blood cells, and the remaining blood is returned to the patient.
• The procedure usually lasts several hours and is performed as an outpatient or short-stay process in most centers.
• Patients are often advised about calcium levels, hydration and possible temporary side effects such as tingling or fatigue.

The collected cells become the starting material that will later be engineered into the CAR-T product.

Step 3 – Manufacturing the CAR-T product

The cells are sent to a specialized GMP (Good Manufacturing Practice) laboratory. There they undergo several controlled steps:

• Activation – T cells are stimulated so they can be efficiently engineered.
• Genetic modification – A viral vector (commonly a lentiviral vector) introduces the chimeric antigen receptor (CAR) gene so the cells can recognize the target (often CD19 on B-cell cancers). Some products also include additional functional modifications.
• Expansion – The engineered cells are grown in number under carefully monitored conditions.
• Quality control and release testing – Multiple tests confirm identity, viability, CAR expression, potency, genetic characteristics and safety (sterility, mycoplasma, endotoxin, etc.) before the product can be released.

The time from collection to ready product is often called the vein-to-vein time. With local manufacturing it can be in the range of roughly two to four weeks once the process is fully operational; exact timing varies by product, laboratory and individual cell behavior. During this period the clinical team may use bridging therapy to control the disease if needed.

Step 4 – Lymphodepleting chemotherapy

A few days before the CAR-T cells are infused, the patient receives a short course of chemotherapy (commonly fludarabine and cyclophosphamide). This is called lymphodepletion. It temporarily reduces the existing immune cells so that the new CAR-T cells have more space and supportive signals to expand after infusion. Side effects of this short chemotherapy can include low blood counts, fatigue and increased infection risk.

Step 5 – CAR-T infusion

The release-tested CAR-T product is given as a single intravenous infusion, similar to a blood transfusion. The infusion itself is usually relatively short. Afterward the patient remains under close observation in the hospital because the most important early side effects tend to appear in the first days to two weeks.

Step 6 – Early monitoring (hospital phase)

This is one of the most critical parts of the process. The care team watches for:

• Cytokine release syndrome (CRS) – fever, low blood pressure, breathing difficulty or other inflammatory signs caused by immune activation.
• Neurologic side effects – confusion, language difficulty, tremors or other changes (sometimes called ICANS).
• Infections and low blood counts.

Hospitals experienced in cellular therapy have protocols and medications ready to manage these events. The length of hospital stay varies; many centers plan for at least one to two weeks of close monitoring, sometimes longer depending on the patient’s course.

Step 7 – Follow-up and longer-term care

After discharge, patients continue regular outpatient visits. Blood counts, immune recovery, possible late infections and disease response (by imaging or other assessments) are monitored. Some effects of treatment, such as low blood counts or reduced immune function, can last weeks to months. Vaccination schedules and infection precautions are often adjusted. Long-term follow-up is standard for this class of therapy.